Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nbqx. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.50 |
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.37 |
| ▸ | CA1 known ✓ | P00915 | 4/20 | 0.37 |
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nbqx SCHEMBL29985796 | 0.99 | MAPT (0.98) | MAPTKMT2AHPGDKDM4EHSD17B10 | |
| Nbqx SCHEMBL29412437 | 0.85 | MAPT (0.74) | MAPTKMT2AHPGDKDM4EHSD17B10 | |
| Nbqx SCHEMBL220464 | 0.85 | MAPT (0.74) | MAPTKMT2AHPGDKDM4EHSD17B10 | |
| Nbqx SCHEMBL26985644 | 0.84 | MAPT (0.73) | MAPTKMT2AHPGDKDM4EHSD17B10 | |
| Nbqx SCHEMBL30728067 | 0.84 | MAPT (0.73) | MAPTKMT2AHPGDKDM4EHSD17B10 | |
| SCHEMBL7100168 | 0.80 | MAPT (0.67) | MAPTKMT2AHPGDKDM4EHSD17B10 | |
| Nbqx SCHEMBL2230845 | 0.79 | MAPT (0.65) | MAPTKMT2AHPGDKDM4EHSD17B10 | |
| SCHEMBL9341166 | 0.76 | KMT2A (0.61) | MAPTKMT2AHPGDKDM4EHSD17B10 | |
| SCHEMBL28120662 | 0.76 | KMT2A (0.61) | MAPTKMT2AHPGDKDM4EHSD17B10 | |
| SCHEMBL12648303 | 0.71 | KDM4E (0.55) | MAPTKMT2AHPGDKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240299680-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2024-09-12 | — | — | US | disclosed |
| US-12005185-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-2776131-B1 | COMPOSITION FOR TREATING OR PREVENTING NEURODEGENERATIVE DISORDERS | BIOLOGISCHE HEILMITTEL HEEL GMBH (DE) | 2024-05-15 | — | — | EP | disclosed |
| US-20240076630-A1 | METHODS FOR GENERATING NEURAL TISSUE AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-03-07 | — | — | US | disclosed |
| US-20240002936-A1 | USE OF BRAIN ORGANOIDS AND SINGLE CELL GENOMICS TO UNDERSTAND AND TREAT NEURODEVELOPMENTAL AND NEUROPSYCHIATRIC DISORDERS | THE BROAD INSTITUTE, INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230191047-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023114462-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230064864-A1 | Neuromodulation Using Electrical Stimulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-02 | — | — | US | disclosed |
| WO-2022094438-A1 | USE OF BRAIN ORGANOIDS AND SINGLE CELL GENOMICS TO UNDERSTAND AND TREAT NEURODEVELOPMENTAL AND NEUROPSYCHIATRIC DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-01-30 | — | — | US | disclosed |
| WO-2018169798-A9 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018169798-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | GABRA4, GABRG1, GABRB2 | THRB 198/4885CA2 1553/4885CA1 876/4885 |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | THRB 1201/4885CA2 289/4885CA1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.